๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Incyte Corporation (INCY)
NASDAQ: INCY ยท Real-Time Price ยท USD
117.80
-1.29 (-1.08%)
At close: Nov 18, 2026, 4:00 PM EST
117.00
-0.80 (-0.68%)
After-hours: Nov 18, 2026, 4:57 PM EST
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

Growth plans center on a $3B-$4B ex-JAKAFI core business by 2030 and phase III execution across MPN, G12D and immunology assets. Key milestones include 989 frontline plans and JAK2 phase I in 2027, plus expected U.S. povorcitinib approval in Q1 2027.

Faisal Khurshid
Biotech Analyst, Jefferies

Biotech analyst at Jefferies. We are here in London at the Jefferies Global Healthcare Conference. Thank you all for joining. Really pleased to have with us today the management team of Incyte. We have Bill Meury, Dave Gardner with me on stage. We have a ton to get through, and I am looking at the timer already ticking down. So Bill, why don't you kick it off, give us some opening remarks?

Bill Meury
President and CEO, Incyte

Great. We are through the end of 2026. I think we are in a much stronger position today than we were at the beginning of 2026. We think about running the company on two dimensions. First, we have a core business ex-JAKAFI, which is solidly on track by 2030 to reach about $3 billion-$4 billion. That is important because it creates a foundation for Incyte and t hen we have a pipeline of phase III assets that today are increasingly de-risked, and what we are focused on is phase III study execution. I think when we look at the pipeline, there are four assets that, on a risk-adjusted basis, could create a great deal of value for the company. That is, of course, povorcitinib, which is under review at the FDA. We have 989, our CALR antibody for MF and ET.

We have our G12D inhibitor for pancreatic cancer, and latarcibart, which is a Protein S modulator for von Willebrand. I think they are high PTS projects and have the potential, on an unadjusted basis, to 2X the company over the long term. The last point I would make is we have an outlier opportunity in TGF-beta by PD-1 for colorectal cancer. We shared data at ESMO several weeks ago on top of FOLFOX/Bev standard of care. Response rates in the all-comers population, PD-L1 positive, and in patients with liver mets was impressive.

T he battleground there is PFS, and we will get data throughout 2027 on that program. On an unadjusted basis, that product could be the largest one we have, but we have to make sure the response rate holds up. Right now, the job is just to continue to execute on the two dimensions of the company that I talked about.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. Awesome, Bill. And Bill, I really like the situation that you're working yourself through, almost on an intellectual basis. It's like biotech circle of life, right? Incyte has had great success with JAKAFI. Now you're trying to reinvent for kind of the next generation. So we got to talk about G12D, we got to talk about CALR, and with Dave here, I want to talk about BD as well. Bill, why don't you decide which one you want to talk about first?

Bill Meury
President and CEO, Incyte

Well, let's start with, since ASH is approaching, I think we can start with 989.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. Yeah, so let's break it down. Can you talk about kind of what you've shown so far with 989, where you're at on pivotal study initiation, and then we can talk about expectations for ASH?

Bill Meury
President and CEO, Incyte

Yeah, so right now, we have a second-line ET study that's being run and a second-line MF study with 989 on conventional endpoints of SVR35, TSS50, and anemia response and w e are getting ready by the middle of 2027 to start a frontline study. Here's what we know right now about the antibody. We know what the benchmarks are in the second-line setting on conventional endpoints, and we know what the benchmarks are in the frontline setting for MF. And 989 has cleared, in our opinion, all the benchmarks in the second-line MF setting.

Now, in the frontline setting, we'll share data at ASH in several weeks and w hat we've always said is that if we can replicate the data that we showed at EHA in a JAK-ineligible population at ASH, we believe we have a strong competitive profile and a line of sight to a successful frontline study and I think you'll find the results on conventional endpoints, SVR35, TSS50, and anemia response, as very, very encouraging. It'll be a function of a discussion with the FDA about whether we design a monotherapy or a monotherapy and combination study. I think the use case for 989 as mono and combo therapy is very relevant. I think there's likelihood that we could have a three-arm study, and you'll be able to see what we see at ASH, but I'm very encouraged about where that program is right now.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. Can you just talk about the nuances around getting a composite endpoint? What does a composite endpoint mean from a biology basis, and the differences between what the two drugs are doing? Why is a composite endpoint potentially beneficial here?

Bill Meury
President and CEO, Incyte

Yeah, it's a really good question. If we were developing another pathway blocker, another JAK inhibitor, or another mechanism, SVR35 and TSS50 could make a great deal of sense. It's symptomatic therapy, b ut 989 is an antibody targeting the driver mutation, CALR, and we believe that we should look at a range of disease dimensions. And in hematology and in the treatment of MF, that includes spleen volume, hemoglobin, platelets, and blast counts. And so as a base case, we assume that we're going to be using conventional endpoints in our phase III study. I think that's the prudent thing to do, b ut we will have a conversation with the agency at the beginning of 2027 to talk about measuring a targeted treatment differently than a pathway blocker. If the FDA prefers the conventional endpoints, we will use the composite endpoint as a powered key secondary endpoint.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. Can you break down sort of, maybe from the agency's perspective as you see it, what are the pros and cons between allowing or disallowing a composite endpoint? Because hearing you talk about this concept, right, like in MF, it's spleen volume and it's TSS. Only one of those is an objective endpoint. When you talk about composite, you're actually talking about objective measures. So, I'm kind of surprised that you're still saying like base case is spleen volume and TSS.

Bill Meury
President and CEO, Incyte

Yeah, I think it's an administrative step in changing an endpoint. While there are precedents at the FDA, it takes a little bit of work. And what the FDA looks for, as many of you may know, you either have to make people feel better or make them live longer. So what they're going to look at is correlation between the individual components of this composite and ultimately outcomes. And we, of course, have data and modeling that we'll share with the division. This will be the first conversation we've had with the agency about changing the endpoint, and we'll provide some sort of an update in the middle of 2027.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. Bill, can I just ask you to clarify that? Because I believe in second-line MF, you guys had at least thought about or considered moving to a composite endpoint. Can you just remind us where did those conversations land and what's different happening here?

Bill Meury
President and CEO, Incyte

Yeah. We talked to the review division about a new endpoint, and of course, the review division said, "You'll need to talk to the surrogate endpoints division." So that's really procedural, and we did not want to wait to start the second-line MF study and t hat's why we started the study and used the composite, as I said, as a powered key secondary endpoint and then f or the frontline study, we have two options here, and it'll be determined when we finish our conversations with the FDA.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. And then can I also ask you to just kind of take a step back and talk about your portfolio approach to myeloproliferative neoplasms? I know you have some development ongoing in JAK2 as well. As you think about the future, how are you thinking about Incyte kind of retaining this ownership of MPNs?

Bill Meury
President and CEO, Incyte

Yeah, it's a good question. There is a great deal of focus right now on 989, but our job is to turn 989 into a franchise. What you're talking about is we have several targeted agents in early stages of development. We, of course, have a next-generation CALR antibody, 798. We have, as you pointed out, a small molecule targeting JAK2V617F, which is a very important driver mutation in MPNs. It's 95% of PV and about 50%-60% of both ET and MF. Our first-generation V617 small molecule, code name 058, was about fivefold selective for mutant cells over wild-type cells.

Our next generation is about 20 times fold more selective for mutant over wild type. One of the problems with targeting JAKV617 is selectivity, and that was the problem we're solving for. We'll be entering phase I in 2027, and that will be an important emerging new asset for us. We also have a T-cell engager, CD3 CALR antibody and so o ur goal is to have a solution for every patient with an MPN by 2030. 989 is the start, and then the other compounds will report out over the next two years.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. And Bill, I know you guys have been kind of leading scientifically here, going back to kind of the origin story of JAKAFI, but obviously, whenever you show something interesting in biotech, it's going to invite a ton of competition. So we're going to see J&J CALR CD3 data at ASH. Lilly did a deal yesterday for CALR. There's a small biotech, Damora, that's developing CALR assets as well. How are you seeing this space, and how are you seeing your capability to win here?

Bill Meury
President and CEO, Incyte

It's a good question. Large, lucrative, attractive markets attract competition. If you're the only one in a market, you should ask yourself why and t here's always going to be someone in your rearview mirror. I think we have all the ingredients to build a best-in-class targeted MPN portfolio, and what we have to focus is on what we can control. I think, across the three domains of MPNs, we have the portfolio that we need.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. Do you feel like 798, your kind of next-gen CALR, do you feel like that kind of protects you against competitive risk?

Bill Meury
President and CEO, Incyte

Yeah, it is a good question. We started working on the next-gen a couple years ago, and we have optimized, in our opinion, every attribute of 989 and t hat means numerically higher affinity. More importantly, that means greater potency. It is four times more potent for type 1 and about 70 times more potent for type 2. It has a much longer half-life of 50- 60 days. It will be a lower dose and put in a pen and so I think we are set up to be out with 989 two years before anybody else, and then follow up with the next-generation antibody shortly thereafter.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. All right, I want to pivot from CALR. I do want to come back to you, Bill, on G12D, but maybe Dave, since it is a pleasure to have you here as well, can you just give us kind of a quick reminder for those of you who do not know you, what your role is at the company, what you have done so far from the BD perspective? And also just remind folks, for those who may not be familiar, what the company's capacity is for BD.

Dave Gardner
Chief Strategy Officer, Incyte

Yeah, sure. Thanks for the question. So my background is I did about 21 years on the buy side, so I have the career of many of you in the audience and t hen I joined about 13, 14 months ago as the Chief Strategy Officer. So business development is one of the major capacities that we undertake in my group. And I would say, our strategy from a business development perspective is, if there is one North Star that we are thinking about, it is really our post-JAKAFI LOE growth rate so t hat 29- 32 window. If we can come out with a top-tier growth rate for the business, I think that will be how we are ultimately valued as an organization in the long run so w e think about that a lot when we talk about business development.

Some of the tenets that we have in place for our framework, we are likely to stick to our three core therapeutic areas, those being hematology, broadly defined, so both malignant and benign hematology, solid tumor oncology with, as you know, we have somewhat of a focus in GI oncology, and then immune-mediated skin conditions where we have one and soon to be two commercial franchises. So we are fortunate in the sense that we have a lot of substrate internally to achieve our goals of our long-term growth rate, and we are hoping to add to that externally and t he three core therapeutic areas that we are already in, as you all know, have a ton of innovation happening both internally and externally, so pretty ripe hunting ground.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. Dave, just two things. Can you speak to sort of your urgency or pace that we should expect on doing deals? And then also, how should we on the investor side, think about Incyte's differentiation when it comes to being the acquirer, right? Oftentimes you might be bidding against larger pharma companies. How should we think about your ability to win these deals?

Dave Gardner
Chief Strategy Officer, Incyte

Yeah. Great question. We ask ourselves that a lot, so o ur urgency is high. The only thing worse than doing no deals would be doing the wrong deal, so we are very careful not to let our urgency take over and do the wrong thing, b ut we are active, engaged, urgent, and across all of our therapeutic areas, pursuing actively BD ideas. I would say that when it comes to capacity, which you asked about, if you just think about how much cash we have on the balance sheet, call it $4 billion, and then you think about how much cash we will generate between now and the LOE, we could pull that forward in very inexpensive debt. You kind of think about $7 billion-$8 billion of total capacity. I think we are unlikely to deploy that all at once.

So what we are looking for is more transactions like Star Vega, which is the one we announced earlier this year. We think that is a really attractive profile, sort of meets that goal of being accretive in the 2029- 2032 period, highly adjacent to our core MPN hematology franchise, and then financially and operationally tractable by Incyte. In terms of how do we win deals, I think we really have to think about how we can outmaneuver in terms of being there early, being there deep, and ultimately, sometimes it can come down to risk appetite. I think Incyte is willing to take calculated risks to make sure we get the right stuff done.

Bill Meury
President and CEO, Incyte

And I would say we try to avoid being the high bidder in a 10-way auction. But given our size, and there is a lot of competition out there is a zone where we operate where $500 million , $1 billion or even $1,500,000,000 opportunity can move the needle for Incyte. It's going to look very different to a top 10 pharma company.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. That makes sense and so I want to talk about G12D. You guys recently had some data at ESMO. I think the Street is well familiar with that. I just want to understand from a strategy perspective, Bill, like how you're seeing your ability to compete here. Like, obviously, there is a kind of a leader who's innovated a ton, who's kind of generated a lot of investor excitement in RevMed. Like, how should we think about your ability to kind of come into this market and have a place here?

Bill Meury
President and CEO, Incyte

Yeah. I think that first, G12D for Incyte can be a major future growth driver. I think when you look at the companies that are doing work in the space, we are right there at the starting point with our G12D inhibitor in terms of its efficacy and tolerability in the frontline setting on top of FOLFIRINOX and Gem/nab. Starting point. I don't see this as a winner take all. I think it's one of the more exciting areas in oncology. I think what's going to determine success for Incyte is systematically expanding the development of G12D, and that means a few things. First, multiple lines of therapy, s o we're looking at adjuvant PDAC, frontline PDAC, and we're also looking at additional tumor types, pancreatic cancer and colorectal cancer.

In colorectal, that would be both frontline and late line, and combinations with a PRMT5 and a PARP inhibitor to create deeper, more durable responses. And if we can do that, and you look at how this market will evolve over the next five years, we will have created a scenario where the use case for our G12D inhibitor applies to a range of potential clinical situations. The enrollment in our phase III study, right, frontline PDAC program is going extremely well. We'll be starting adjuvant PDAC as well as our second line colorectal study in 2027.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. Bill, as you think about your strategy for the G12D, how are you thinking about fast following where the field is going versus innovating b ecause as I look at your G12D strategy, I feel like you have done a little bit of both, right? You have PRMT5, but then in colorectal, you are doing the larotrectinib combo, but then on combining with the PARP inhibitor, that is really novel, but it has a really fascinating paper describing the rationale for that.

Bill Meury
President and CEO, Incyte

Yeah, there is multiple different approaches. In second line or late line CRC with cetuximab, that is a fast-to-market approach. Then, of course, we are going to look at a combination with Peto in the frontline CRC setting, where you are looking to be the, what we think that is a potentially differentiated EGFR and I think you cannot predict the future. You just have to be prepared for the range of potential outcomes, and I think this market will look very different in five years than it does today, with dara being the starting point. We have the R&D capabilities and the resources to effectively execute this program. This has the potential for Incyte, without making heroic assumptions about Incyte's share of the overall global PDAC market, both in pancreatic and colorectal, to be a real needle mover and a multi-billion dollar opportunity.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. Can you just talk about your colorectal cancer strategy? Because, obviously, you guys have announced a second-line pivotal study for colorectal cancer. RevMed has announced plans to do a frontline study in colorectal cancer. How should we think about that competitive dynamic and what you need to do to win a portion of this market at the end of the day?

Bill Meury
President and CEO, Incyte

Yeah. It is not an either/or. For us, it is an and. The problem in second and third-line colorectal cancer is patients run out of effective treatment options, the standard of care right now is LONSURF/Bev, and there is two other treatments of EGFR and regorafenib. When you look at standard of care, the response rates are relatively low. If you look at PFS, it could range from two months to five months. We shared data from our second-line CRC study with G12D and EGFR and showed a 36% response rate versus 8%, and a PFS about seven months and s o, we believe we can improve in a G12D population outcomes in the late-line setting. When you look at frontline, we turn to a partnership with Genmab for Peto, we believe that that could be a differentiated EGFR inhibitor. We may be a little bit later, but we think we may have a better regimen.

Faisal Khurshid
Biotech Analyst, Jefferies

And then I want to switch gears and talk about povorcitinib. So you just got the European approval yesterday. I was telling your team, I was like, "It's very rare that you see a drug name on approval and think like, "Oh, yeah, it's actually a decent name." You guys did well there. Can you tell us about povo and what we should expect over 2027?

Bill Meury
President and CEO, Incyte

Yeah. The sheer data and quality of data in our filings, both in the EU and the U.S., I think was very impressive. I think the probability for approval in the United States is very high, and we expect that in the first quarter. povorcitinib is going to be the first oral FDA-approved multi-cytokine inhibitor for one of the more difficult dermatological conditions you can have, HS. Right now, patients can get a steroid or an antibiotic or an IL-13, but there's nothing in between. We studied both a pre and a post-biologic population, and I think we will capture patients at two inflection points. That is, before a biologic and after a biologic.

The data with povorcitinib relative to an IL-17 is very impressive, whether you look at HiSCR50, 75, 90, or 100, at week 24 or week 54, it has biologic efficacy. The pain relief of the JAK inhibitor is consistent and remarkable. Most importantly, JAK inhibitors work fast. Our view is that the HS indication could be $500 million-$1 billion. We also will have data on prurigo nodularis at the end of the year. That is an itch disease. JAK inhibitors were made for itch. Then we have data in vitiligo. Our immunology business, which is OPZELURA and povorcitinib, may never be as big as our hematology and oncology business, assuming we execute in those two areas, but on an absolute basis, can be incredibly important and becomes a funding vehicle for the rest of the company.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. And then, as you think about kind of trying to get that pre-biologic positioning, what do you need to accomplish from a market access perspective in the U.S. to be able to enable that?

Bill Meury
President and CEO, Incyte

Yeah, it's a good question. We'll face, like any company, three situations with health plans: open access, PA to label, and then a step edit behind biosimilar Humira. It will be a mix of those. There is a price point that we can set for this product that's going to make sense for PBMs and health plans, and that makes sense for Incyte. I do not believe that that is going to be a friction point in the launch. Most important thing for us to do right now is to get dermatologists all across the United States to try povorcitinib.

If it performs in the real world like it did in the clinical trial setting, we should do extremely well. I think one of the things in HS that doesn't exist right now, as I pointed out, is an oral anti-inflammatory. And i f you take a look at what icotrokinra has done in psoriasis, or even look at GLP-1s. I read a statistic the other day, 40% of oral GLP-1 use is not patients who were on the injection. I think we're likely to unlock a large pool of patients, given that this is an oral medication with biologic-like efficacy.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. Then, just kind of conceptually on povo, right? You've talked about MPNs as kind of a can't lose situation for you. For povo, I mean, you have more degrees of freedom here in terms of what you can do on the commercial side. Does that give you kind of more leverage to be able to kind of like toy around with price or access or different strategies to try to kind of tap into this market?

Bill Meury
President and CEO, Incyte

Yeah. I think the pricing framework in the market is set because you have RINVOQ and you have the IL-17s. So essentially, pharmaceutical pricing starts with what is the ceiling and what is the floor? Now we have IP on povorcitinib all the way to the end of the next decade and so w hen you think about exclusivity, that will dictate how you think about your price volume analysis. I really believe, and we've had already 80 conversations with 80 different payers about povorcitinib, I believe we're going to be able to get the access that we need in 2027 and 2028 when we launch the product.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. So Bill, just to kind of close us out here, I mean, you're kind of in this post-JAKAFI reinvention story. There are several moving parts as part of your strategy to kind of fill that gap across all of these different things, right? I know we talk a lot about CALR, we talk a lot about G12D, we talk a little bit about povo. What do you think is under the radar and underappreciated by investors that could be a needle mover in the next five years?

Bill Meury
President and CEO, Incyte

I think appreciation for the MPN franchise will come with time. Until you get something into phase I and you have meaningful data that enables phase III, where there's real visibility, it's hard. I think that MPN franchise will look It already looks very different today than it did a year ago, and I think by the beginning of 2028, you will see more assets that have the same potential as 989. I think as it relates to our GI oncology business, there's going to be more and more visibility into our ability to compete in PDAC with G12D, and then we'll learn whether or not our TGF-beta by PD-1 is going to turn out to be a true outlier opportunity for Incyte.

Faisal Khurshid
Biotech Analyst, Jefferies

Got it. Awesome. Thanks so much, Bill. Thank you, Dave, for being here.

Bill Meury
President and CEO, Incyte

Great.

Dave Gardner
Chief Strategy Officer, Incyte

Thank you.